Catalyst Biosciences participates in a conference call with LifeSci Capital » 12:1301/1501/15/21
Catalyst's management team provides an overview of the Company's recently introduced complement programs, as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen, on a conference call to be held on January 19 at 1pm hosted by LifeSci Capital. Webcast Link
|Over a week ago|
Nurix Therapeutics expands strategic collaboration with Sanofi » 07:0901/0701/07/21
Nurix Therapeutics (NRIX)…
Nurix Therapeutics (NRIX) announced the expansion of its global strategic collaboration with Sanofi (SNY) to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas. Sanofi has exercised its option to expand the number of targets in the collaboration agreement from three to a total of five targets. With the expansion, Nurix receives a payment of $22M, in addition to the previously received upfront payment of $55M. Nurix is also eligible to receive up to approximately $2.5B in total payments based on the successful completion of certain research, pre-clinical, clinical, regulatory and sales milestones. As part of the multi-year collaboration signed in December 2019, Nurix is using its proprietary drug discovery platform, DELigase, that integrates its DNA-encoded libraries and its portfolio of E3 ligases to create small molecules designed to induce degradation of specified drug targets. Sanofi will have exclusive rights and be responsible for clinical development and commercialization of drug candidates resulting from the work while Nurix will retain the option to co-develop and co-promote up to two products in the United States under certain conditions. Nurix will be eligible for royalties on annual net sales of any commercial products that may result from the collaboration, excluding sales in the United States of any products for which Nurix exercises its option to co-develop and co-promote, for which Nurix and Sanofi share U.S. profits and losses evenly, and Nurix will be eligible to receive royalties on ex-U.S. net sales on all optioned products. The collaboration excludes Nurix's wholly owned pipeline for which Nurix retains all rights.
|Over a month ago|
Catalyst Biosciences to host research and development conference call » 11:2512/1412/14/20
Management holds a…
Catalyst Biosciences to host research and development conference call » 04:5512/1412/14/20
Management holds a…
Geron opens patient screening, enrollment for IMpactMF trial » 08:3212/1112/11/20
Geron announced the…
Geron announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a telomerase inhibitor, in refractory myelofibrosis, or MF. Geron plans for IMpactMF to evaluate imetelstat compared to best available therapy in approximately 320 patients with Intermediate-2 or High-risk MF. Patients eligible for the trial will be required to be non-responsive, or refractory, to treatment with a JAK inhibitor. The primary efficacy endpoint for the Phase 3 trial is overall survival, or OS. Secondary endpoints include symptom response, spleen response, progression free survival, duration of response, safety, pharmacokinetics and patient reported outcomes. Geron plans to engage over 150 sites to participate in IMpactMF across North America, South America, Europe and Asia, with the majority of clinical sites expected to be open for screening and enrollment in 2021, subject to potential delays or interruptions associated with the evolving and uncertain effects of the COVID-19 pandemic.
Geron achieves 50% enrollment in IMerge Phase 3 clinical trial of imetelstat » 08:3912/1012/10/20
Geron announced achievement of 50% enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes, or MDS. Data from the IMerge Phase 2 were recently presented at the American Society of Hematology Annual Meeting and support the ongoing Phase 3. The IMerge Phase 3 is a double-blind, randomized, placebo-controlled clinical trial with registration intent. The trial is designed to enroll approximately 170 transfusion dependent patients with Low or Intermediate-1 risk MDS, or lower risk MDS, who have relapsed after or are refractory to prior treatment with an erythropoiesis stimulating agent, or ESA. The primary endpoint is the rate of red blood cell, or RBC, transfusion independence, or TI, for a consecutive period of eight weeks or longer, or 8-week RBC-TI rate. Key secondary endpoints include the rate of RBC-TI of at least 24 weeks, or 24-week RBC-TI rate, rate of hematologic improvement-erythroid, defined as a reduction of at least four units of RBC transfusions over eight weeks compared with the prior RBC transfusion burden, and duration of transfusion independence. The company continues to expect full enrollment in the IMerge Phase 3 in the second quarter of 2021. As long as enrollment is completed by the end of the first half of 2021, Geron maintains its projection of top-line results from IMerge to be available in the second half of 2022.
Catalyst Biosciences to host research and development conference call » 15:3812/0912/09/20
Management holds a…
Sutro Biopharma 6M share Secondary priced at $21.00 » 06:0912/0912/09/20
The deal size was…
The deal size was increased to 6M share from 5M shares and priced below the last closing price of $22.22. Cowen, Piper Sandler and Wells Fargo are acting as joint book running managers for the offering.
Fly Intel: After-Hours Movers » 18:5812/0712/07/20
SFIX, SMAR, COUP, RTX, TOL, CASY, MRNS, ARCT, IBIO, GRWG, SQNS, STRO
Check out this evening's…
Sutro Biopharma files to sell 5M shares of common stock » 16:0312/0712/07/20
Cowen, Piper Sandler and…
Cowen, Piper Sandler and Wells Fargo Securities are acting as joint book-running managers in the offering. Wedbush PacGrow and JMP Securities are acting as co-managers for the offering.